Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 10/20 | 0.54 |
| ▸ | VKORC1 | Q9BQB6 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NQO1 | P15559 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6175609 | 1.00 | CYP2C9 (0.54) | CYP2C9VKORC1KDM4EALDH1A1ALB | |
| SCHEMBL6174912 | 1.00 | CYP2C9 (0.54) | CYP2C9VKORC1KDM4EALDH1A1ALB | |
| SCHEMBL6175124 | 1.00 | CYP2C9 (0.54) | CYP2C9VKORC1KDM4EALDH1A1ALB | |
| SCHEMBL6174948 | 1.00 | CYP2C9 (0.54) | CYP2C9VKORC1KDM4EALDH1A1ALB | |
| SCHEMBL6173543 | 0.96 | CYP2C9 (0.55) | CYP2C9VKORC1KDM4EALDH1A1ALB | |
| SCHEMBL7485149 | 0.94 | CYP2C9 (0.48) | CYP2C9VKORC1KDM4EALDH1A1ALB | |
| SCHEMBL7476525 | 0.94 | CYP2C9 (0.51) | CYP2C9VKORC1KDM4EALDH1A1ALB | |
| SCHEMBL6173770 | 0.91 | CYP2C9 (0.60) | CYP2C9VKORC1KDM4EALDH1A1ALB | |
| SCHEMBL7478059 | 0.91 | CYP2C9 (0.44) | CYP2C9VKORC1KDM4EALDH1A1ALB | |
| SCHEMBL9283393 | 0.91 | CYP2C9 (0.50) | CYP2C9VKORC1KDM4EALDH1A1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547335-A2 | ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | Modex Therapeutics, Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| EP-4547711-A2 | ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | Modex Therapeutics, Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| CN-119948053-A | Anti-SARS-CoV-2 antigen binding polypeptides, polypeptide complexes, and methods of use thereof | 摩德斯医疗股份有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119836434-A | Anti-SARS-CoV-2 antigen binding polypeptides, polypeptide complexes, and methods of use thereof | 摩德斯医疗股份有限公司 | 2025-04-15 | — | — | CN | claimed |
| WO-2024007013-A2 | ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | MODEX THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2024007012-A2 | ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | MODEX THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | claimed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | claimed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | claimed |
| EP-1203770-B1 | Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hyperplasia and other diseases | UPJOHN CO (US) | 2005-03-09 | — | — | EP | claimed |
| EP-0668860-B1 | PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES | UPJOHN CO (US) | 2002-09-11 | — | — | EP | claimed |
| EP-1203770-A1 | Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hyperplasia and other diseases | PHARMACIA & UPJOHN COMPANY (US) | 2002-05-08 | — | — | EP | claimed |
| EP-0977570-A1 | QUINOXALINE IN TRIPLE COMBINATION WITH PROTEASE INHIBITORS AND REVERSE TRANSCRIPTASE INHIBITORS AS MEDICINES FOR TREATING AIDS | BAYER AG (DE) | 2000-02-09 | — | — | EP | claimed |
| WO-1998032442-A1 | QUINOXALINE IN TRIPLE COMBINATION WITH PROTEASE INHIBITORS AND REVERSE TRANSCRIPTASE INHIBITORS AS MEDICINES FOR TREATING AIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-07-30 | — | — | WO | claimed |
| EP-0728481-A2 | Use of quinoxaline and protease inhibitors in a composition for the treatment of AIDS and/or HIV infections | BAYER AG (DE) | 1996-08-28 | — | — | EP | claimed |
| EP-0668860-A1 | PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES | PHARMACIA & UPJOHN COMPANY (US) | 1995-08-30 | — | — | EP | claimed |
| WO-1994011361-A1 | PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES | THE UPJOHN COMPANY (US) | 1994-05-26 | — | — | WO | claimed |
| US-12453717-B1 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | Accencio LC (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250326823-A1 | Antigen Binding Polypeptides, Polypeptide Complexes and Methods of Use Thereof | MODEX THERAPEUTICS, INC. | 2025-10-23 | — | — | US | disclosed |
| EP-0668860-A1 | PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES | PHARMACIA & UPJOHN COMPANY (US) | 1995-08-30 | — | — | EP | disclosed |
| WO-1994011361-A1 | PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES | THE UPJOHN COMPANY (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12453717-B1 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | ACE, ACE2, TMPRSS2 | CYP2C9 568/4885VKORC1 3374/4885KDM4E 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.